{ "items": [ "\n\n
\n \n 7 December 2021\n \n
\n\n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n \n \n \n \n\n\n \n 1 November 2021\n \n
\n\n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n \n \n \n \n\n\n \n 14 July 2021\n \n
\n\n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n \n \nOxford Trauma are pleased to open their first overseas site for the SCIENCE study.
\n \n\n\n \n 14 July 2021\n \n
\n\n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n \n \nA trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.
\n \n\n\n \n 12 July 2021\n \n
\n\n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n \n \nThe Partial Rotator Cuff Tear Repair Trial (PRoCuRe) is open to recruitment at Oxford University Hospitals NHS Foundation Trust after achieving OCTRU Green Light approval!
\n \n\n\n \n 10 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n \n \n \n \n\n\n \n 4 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n \n \nOCTRU have now given Green Light approval for IMP MEL to open. This is a phase 1 first-in-human dose finding/randomised phase 2 study of IMM60 and pembrolizumab in advanced melanoma and NSCLC.
\n \n\n\n \n 25 May 2021\n \n
\n\n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n \n \nThe WISE Study - Wrist Injury Strengthening Exercise: a randomised multicentre feasibility study of resistance exercise versus usual care for optimising function after distal radius fracture in adults aged 50 years or over has now received OCTRU Green Light approval and has opened to recruitment.
\n \n\n\n \n 20 May 2021\n \n
\n\n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n \n \nResearchers across the world celebrate International Clinical Trials Day today. We have produced a short animation this year to mark the occasion...
\n \n\n\n \n 6 May 2021\n \n
\n\n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n \n \nA clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.
\n \n\n\n \n 5 May 2021\n \n
\n\n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n \n \nOlder patients with hip fractures recover better if they receive treatment under the supervision of both a surgeon and a specialist in elderly care; are checked to avoid future falls; and are assessed for memory problems.
\n \n\n\n \n 18 February 2021\n \n
\n\n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n \n \nThe AVID-CC trial has received OCTRU Green Light approval and is now open to recruitment!
\n \n\n\n \n 9 February 2021\n \n
\n\n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n \n \nThe results of the WHiTE Four clinical trial for the treatment of fragility hip fractures have been published in The Bone and Joint Journal.
\n \n\n\n \n 5 January 2021\n \n
\n\n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n \n \nThe WHiTE Four trial has now published its results in The Bone & Joint journal.
\n \n\n\n \n 18 December 2020\n \n
\n\n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n \n \nThe FUTURE GB Trial has received OCTRU Green Light approval and is now open to recruitment!
\n \n\n\n \n 7 December 2020\n \n
\n\n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n \n \nThe ARCADIAN trial has received OCTRU Green Light approval and has now begun to open sites to recruitment!
\n \n\n\n \n 10 November 2020\n \n
\n\n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n \n \nResearchers in Oxford are looking to recruit women who have painful osteoarthritis in joints of their hands, after resuming a study that was paused due to the COVID crisis.
\n \n\n\n \n 29 October 2020\n \n
\n\n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n \n \nThe HUSH trial has received OCTRU Green Light approval and is now open to recruitment!
\n \n\n\n \n 30 September 2020\n \n
\n\n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n \n \nResearchers at the University of Oxford are starting a new study to explore the effectiveness of the anti-tumour necrosis factor (anti-TNF) drug adalimumab as a treatment for patients with COVID-19 in the community, especially care homes. The AVID-CC trial, which will be conducted by Oxford Clinical Trials Research Unit (OCTRU), will enrol up to 750 patients from community care settings throughout the UK.
\n \n\n\n \n 16 September 2020\n \n
\n\n \n\n \n\n \n \n \n \n OCTRU\n \n \n\n \n\n\n
\n \n\n \n \n \nCBBC's Operation Ouch have been helping to raise awareness of participation in clinical trials for children.
\n \n\n